4 results match your criteria Psoriasis Forum [Journal]

  • Page 1 of 1

Biomarkers to Diagnose Early Arthritis in Patients With Psoriasis.

Psoriasis Forum 2012 ;18(2):2-10

Allergy/Immunology & Rheumatology, University of Rochester Medical School, Rochester, New York.

Background: Psoriatic arthritis is a potentially destructive, inflammatory joint disease that affects 20% to 30% of patients with psoriasis. Psoriasis precedes the onset of joint inflammation by approximately 10 years, providing a unique opportunity to intervene and prevent or delay onset of musculoskeletal manifestations. The emergence of sensitive imaging modalities and cellular biomarkers may facilitate early identification of patients with psoriasis who have subclinical joint disease and might help stratify patients with an early onset of arthritis. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4241968PMC
January 2012
10 Reads

Hydroxyurea for the Treatment of Psoriasis including in HIV-infected Individuals: A Review.

Psoriasis Forum 2011 ;17(3):180-187

Department of Dermatology, Psoriasis and Skin Treatment Center, University of California, San Francisco, California, USA.

Hydroxyurea is a drug that has been long forgotten for the treatment of psoriasis. In addition to its anti-psoriatic effects, it has also been shown to have antiviral effects. This dual effect makes it a drug that dermatologists may want to consider when treating psoriasis in HIV-infected individuals. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4205952PMC
January 2011
9 Reads

How Long Does the Benefit of Biologics Last? An Update on Time To Relapse and Potential for Rebound of Biologic Agents for Psoriasis.

Psoriasis Forum 2010 ;16(2):36-42

Department of Dermatology, University of California, San Francisco, California.

The biologic agents vary considerably in terms of their long-term duration of effect. Using the definitions provided by the National Psoriasis Foundation Medical Board, the objective of this review was to compare all biologic agents with respect to time to relapse and potential for rebound. Overall, alefacept had the longest off-treatment benefit (29. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4205949PMC
January 2010
14 Reads

Which Psoriasis Patients Develop Psoriatic Arthritis?

Psoriasis Forum 2010 ;16(4):17-25

Department of Dermatology and Psoriasis Treatment Center, University of California-San Francisco, San Francisco, California.

Psoriatic arthritis is a major comorbidity of psoriasis that significantly impairs quality of life and physical function. Because skin lesions classically precede joint symptoms, dermatologists are in a unique position to identify patients at risk for psoriatic arthritis before irreversible joint damage occurs. Here we review the literature to identify the clinical and genetic factors most highly associated with development of psoriatic arthritis, with the goal of assisting dermatologists in risk-stratifying their psoriasis patients. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4206220PMC
January 2010
8 Reads
  • Page 1 of 1